<DOC>
	<DOC>NCT01358175</DOC>
	<brief_summary>This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.</brief_summary>
	<brief_title>16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria: Male or nonpregnant, nonlactating female patients at least 18 years of age Diagnosis of moderate to severe AS with prior documented radiologic evidence (Xray) fulfilling the Modified New York criteria for AS (1984) Patients should have been on NSAIDs with an inadequate response Patients who are regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose Patients who have been on an antiTNFα agent (not more than one) must have experienced an inadequate response Exclusion criteria: Chest Xray with evidence of ongoing infectious or malignant process Patients with total ankylosis of the spine Patients previously treated with any biological immunomodulating agents except for those targeting TNFα Previous treatment with any celldepleting therapies Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>AS</keyword>
	<keyword>ASAS</keyword>
	<keyword>inflammatory back pain</keyword>
</DOC>